Novo Nordisk to cut 400 jobs at Bloomington, Indiana site

Pharmaceutical giant cites workforce reduction at its drug manufacturing facility

Mar. 31, 2026 at 5:07pm

Got story updates? Submit your updates here. ›

A high-end, photorealistic studio still-life photograph featuring a neatly arranged set of pharmaceutical pill bottles, syringes, and other medical equipment, all rendered in clean, polished materials against a plain white background. The objects are lit dramatically to symbolize the complex business and regulatory challenges facing the pharmaceutical industry.As the pharmaceutical industry faces workforce reductions, the stark stillness of this studio setup reflects the human impact behind the business decisions.Bloomington Today

Novo Nordisk, the company behind diabetes drugs Ozempic and Wegovy, has announced it will cut around 400 jobs at its Bloomington, Indiana manufacturing site, representing over 20% of the workforce. The layoffs will take effect in early May, with the company stating it remains committed to the site and will continue to employ around 1,400 people.

Why it matters

The job cuts at Novo Nordisk's Bloomington facility are a significant blow to the local economy, as the site has been a major employer in the area. The layoffs come just months after a previous round of cuts at the same location when it was owned by Catalent, highlighting the volatility in the pharmaceutical manufacturing industry.

The details

Novo Nordisk confirmed the 'workforce reduction of approximately 400 positions' at its Bloomington drug manufacturing site. The company said it will continue to employ around 1,400 people at the facility, calling it a 'critical part of U.S. manufacturing.' Bloomington Mayor Kerry Thomson acknowledged the layoffs and said the city will work to connect affected employees with support and new job opportunities.

  • The layoffs will occur at the beginning of May 2026.
  • In December 2022, the previous owner of the site, Catalent, announced it was cutting more than 400 jobs in Bloomington.

The players

Novo Nordisk

A global pharmaceutical company that produces diabetes drugs like Ozempic and Wegovy. Novo Nordisk acquired the Bloomington manufacturing site in December 2024 after it was previously owned by Catalent.

Kerry Thomson

The mayor of Bloomington, Indiana, who acknowledged the Novo Nordisk layoffs and said the city will work to support affected employees.

Lars Arnoldsen

The site head at Novo Nordisk's Bloomington facility, who reportedly reached out to the mayor to share news of the layoffs.

Catalent

A third-party drug manufacturing company that previously owned the Bloomington site, before it was acquired by Novo Nordisk in 2024.

Got photos? Submit your photos here. ›

What they’re saying

“Our focus is on the individuals affected. We know this is a difficult moment for many and we are committed to helping ensure that those impacted have clear pathways forward.”

— Kerry Thomson, Mayor of Bloomington

What’s next

As of 12 p.m. Tuesday, a WARN notice regarding the Novo Nordisk layoffs had not been filed with the State of Indiana. This notice is required by law when a company plans large-scale layoffs.

The takeaway

The job cuts at Novo Nordisk's Bloomington facility are a significant setback for the local economy, coming just months after the previous owner, Catalent, also announced major layoffs at the same site. This highlights the volatility and uncertainty facing the pharmaceutical manufacturing industry, and the importance of diversifying the local economy to reduce the impact of such disruptions.